Gastric Cancer - Global Clinical Trial Landscape (2024)

Gastric cancer, the fifth most common cancer globally, is heavily influenced by factors such as family history, Helicobacter pylori infection, and lifestyle. Early stages often show few symptoms, but advanced stages can lead to severe issues like weight loss and pain. Survival rates vary, with five-year rates of 75% for localized, 35% for regional, and just 7% for metastatic cases. In 2022, nearly 970,000 new cases were reported, with the highest incidence in Asia.

Treatment options include surgery, radiation, chemotherapy, targeted therapies, and immunotherapy. Guidelines recommend platinum-based chemotherapy and trastuzumab for HER2-positive cases, with nivolumab or pembrolizumab for PD-L1 positive cases. For second-line treatment, ramucirumab plus paclitaxel is preferred.

Since 2019, over 2,000 gastric cancer trials have been initiated, led by Asia-Pacific, North America, and Europe. Key players include Mainland China, the US, Spain, France, and Israel. The drug pipeline features HER2-targeting antibodies and PD-1/PD-L1 inhibitors, with ongoing trials exploring new immunotherapies and antibody-drug conjugates.

Research continues to evolve with advances in systemic, targeted, and immunotherapies, offering new hope for improved treatments. Discover the latest in gastric cancer research with this detailed report, highlighting new therapies, clinical trials, and future innovations.